Reversal of phenylpropanolamine anorexia in rats by the alpha-1 receptor antagonist benoxathian

doi:10.1016/0091-3057(91)90261-Y

Pharmacology Biochemistry and Behavior

Volume 38, Issue 4, April 1991, Pages 905-908

https://doi.org/10.1016/0091-3057(91)90261-Y Get rights and content

Abstract

Phenylpropanolamine (PPA) is a phenethylamine anorectic drug that exerts direct agonist effects predominantly on alpha-1 adrenergic receptors, with some alpha-2 adrenergic activity. Direct injections of PPA as well as the alpha-1 agonist 1-phenylephrine into rat paraventricular nucleus (PVN) suppress feeding. In the present study, we evaluate the hypothesis that systemic PPA acts within the PVN on an alpha-1 receptor population to suppress feeding. Accordingly, adult male rats were prepared with a unilateral guide cannula aimed at the PVN. Microinjection of the alpha-1 adrenergic receptor antagonist benoxathian (0, 2.5, 5.0 or 10.0 nmol) into the PVN was found to have no effect on baseline feeding behavior. Microinjection of 10.0 nmol benoxathian into the PVN completely reversed the anorexia induced by 2.5, 5.0 or 10.0 mg/kg PPA (IP), yet did not alter the hypodipsia produced by PPA. These data strongly suggest that PPA anorexia is mediated by an alpha-1 adrenergic satiety mechanism within the PVN.

References (16)

D. Hoyer et al.
Subtypes of alpha1-adrenoceptors in hippocampus of pigs, guinea-pigs, calves and humans: regional differences
Eur. J. Pharmacol.
(1990)
S.F. Leibowitz
Hypothalamic paraventricular nucleus: Interaction between α₂-noradrenergic system and circulating hormones and nutrients in relation to energy balance
Neurosci. Biobehav. Rev.
(1988)
S.F. Leibowitz et al.
Distribution of alpha-adrenergic, beta-adrenergic and dopaminergic and dopaminergic receptors in discrete hypothalamic areas of rat
Brain Res.
(1982)
M. Massi et al.
Hypotensive effect in dogs and rats of intravenous injections of the alpha1-adrenoceptor antagonist benoxathian
Pharmacol. Res. Commun.
(1986)
C.R. Roland et al.
Hypophysectomy disturbs the noradrenergic feeeding system of the paraventricular nucleus
Psychoneuroendocrinology
(1985)
P.J. Wellman
A review of the physiological bases of the anorexic action of phenylpropanolamine (d,1-norephedrine)
Neurosci. Biobehav. Rev.
(1990)
P.J. Wellman et al.
Effects of phenylpropanolamine on gastric retention in the adult rat
Brain Res. Bull.
(1986)
P.J. Wellman et al.
Effects of paraventricular hypothalamic microinjections of phenylpropanolamine and d-amphetamine on mash intake in rats
Brain Res. Bull.
(1990)

There are more references available in the full text version of this article.

Cited by (40)

New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier?
2010, Pharmacology Biochemistry and Behavior
Citation Excerpt :
Consistent with the opposing roles of α1 and α2 adrenoceptors within the noradrenergic system, these subtypes exert opposing actions on feeding and body weight. Thus, pharmacological studies suggest that α1AR agonists may reduce feeding (Morien et al., 1993), at least in part by activation of receptors located in the hypothalamus (Wellman and Davies, 1991, 1992). By contrast, activation of α2ARs particularly by infusion into the paraventricular nucleus of the hypothalamus increases feeding by increasing meal size but leaves meal frequency unaffected (Shor-Posner et al., 1998).
In this review we assess the range of centrally active anorectics that are either in human clinical trials, or are likely to be so in the near future. We describe their weight loss efficacy, mode of action at both pharmacological and behavioural levels, where understood, together with the range of side effects that might be expected in clinical use. We have however evaluated these compounds against the considerably more rigorous criteria that are now being used by the Federal Drugs Agency and European Medicines Agency to decide approvals and market withdrawals. Several trends are evident. Recent advances in the understanding of energy balance control have resulted in the exploitation of a number of new targets, some of which have yielded promising data in clinical trials for weight loss. A second major trend is derived from the hypothesis that improved weight loss efficacy over current therapy is most likely to emerge from treatments targeting multiple mechanisms of energy balance control. This reasoning has led to the development of a number of new treatments for obesity where multiple mechanisms are targeted, either by a single molecule, such as tesofensine, or through drug combinations such as qnexa, contrave, empatic, and pramlintide + metreleptin. Many of these approaches also utilise advances in formulation technology to widen safety margins. Finally, the practicality of peptide therapies for obesity has become better validated in recent studies and this may allow more rapid exploitation of novel targets, rather than awaiting the development of orally available small molecules. We conclude that novel, more efficacious and better tolerated treatments for obesity may become available in the near future.
Beneficial effects of desipramine on cognitive function of chronically stressed rats are mediated by α<inf>1</inf>-adrenergic receptors in medial prefrontal cortex
2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Chronic stress is a risk factor for many psychopathological conditions, including depression and anxiety disorders. Cognitive impairments associated with prefrontal cortical dysfunction are a major component of such illnesses. Using an attentional set-shifting test (AST), we have previously shown that elevating noradrenergic activity in rat medial prefrontal cortex (mPFC) can facilitate cognitive set-shifting, and that chronic unpredictable stress (CUS) caused set-shifting deficits. It is not known, however, if noradrenergic modulatory function is compromised by chronic stress, perhaps contributing to the stress-induced cognitive deficit. Thus, the first study investigated whether acutely elevating noradrenergic activity in mPFC still enhances cognitive function after chronic stress. As previously demonstrated, CUS impaired cognitive set-shifting on the AST. This deficit was abolished by acute systemic administration of the α₂-adrenergic autoreceptor antagonist, atipamezole. Microdialysis revealed no differences in extracellular norepinephrine (NE) levels in mPFC of CUS-exposed and unstressed control rats at baseline or during behavioral testing, and comparable increases after atipamezole. In the second experiment, rats were treated chronically with the selective NE reuptake blocker, desipramine, during the CUS treatment through behavioral testing. Again, CUS impaired cognitive set-shifting in vehicle-treated rats, and chronic desipramine treatment prevented such deficits. Acute blockade of post-synaptic α₁-adrenergic receptors in mPFC prior to testing blocked the beneficial effect of desipramine on cognitive set-shifting. These results suggest that desipramine restores cognitive set-shifting capability that has been compromised by chronic stress by activating α₁-adrenergic receptors in the mPFC. Thus, noradrenergic modulatory capability in mPFC remains intact after CUS, and this represents one possible substrate by which antidepressants may exert their beneficial effects in the treatment of depression.
(1R, 3S)-(-)-Trans-PAT: A novel full-efficacy serotonin 5-HT<inf>2C</inf> receptor agonist with 5-HT<inf>2A</inf> and 5-HT<inf>2B</inf> receptor inverse agonist/antagonist activity
2009, European Journal of Pharmacology
The serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C G protein-coupled receptors signal primarily through Gα_q to activate phospholipase C (PLC) and formation of inositol phosphates (IP) and diacylglycerol. The human 5-HT_2C receptor, expressed exclusively in the central nervous system, is involved in several physiological and psychological processes. Development of 5-HT_2C agonists that do not also activate 5-HT_2A or 5-HT_2B receptors is challenging because transmembrane domain identity is about 75% among 5-HT₂ subtypes. This paper reports 5-HT₂ receptor affinity and function of (1R,3S)-(−)-trans-1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene (PAT), a small molecule that produces anorexia and weight-loss after peripheral administration to mice. (−)-Trans-PAT is a stereoselective full-efficacy agonist at human 5-HT_2C receptors, plus, it is a 5-HT_2A/5-HT_2B inverse agonist and competitive antagonist. The K_i of (−)-trans-PAT at 5-HT_2A, 5-HT_2B, and 5-HT_2C receptors is 410, 1200, and 37 nM, respectively. Functional studies measured activation of PLC/[³H]-IP formation in clonal cells expressing human 5-HT₂ receptors. At 5-HT_2C receptors, (−)-trans-PAT is an agonist (EC₅₀ = 20 nM) comparable to serotonin in potency and efficacy. At 5-HT_2A and 5-HT_2B receptors, (−)-trans-PAT is an inverse agonist (IC₅₀ = 490 and 1,000 nM, respectively) and competitive antagonist (K_B = 460 and 1400 nM, respectively) of serotonin. Experimental results are interpreted in light of molecular modeling studies indicating the (−)-trans-PAT protonated amine can form an ionic bond with D3.32 of 5-HT_2A and 5-HT_2C receptors, but, not with 5-HT_2B receptors. In addition to probing 5-HT₂ receptor structure and function, (−)-trans-PAT is a novel lead regarding 5-HT_2C agonist/5-HT_2A inverse agonist drug development for obesity and neuropsychiatric disorders.
Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability
2006, Neuroscience
The brain noradrenergic system is thought to facilitate neuronal processes that promote behavioral activation, alertness, and attention. One region in which norepinephrine may exert such effects is the medial prefrontal cortex, which has been implicated in many cognitive functions including arousal, attention, motivation, working memory, response inhibition, and behavioral flexibility. The present study addressed the modulatory influence of noradrenergic neurotransmission in medial prefrontal cortex on cognitive function in rats, as measured by performance in an attentional set shifting task. In experiment 1, we tested effects of increasing and decreasing brain noradrenergic neurotransmission by systemic administration of the α₂-adrenergic autoreceptor antagonist and agonist drugs, atipamezole and clonidine, respectively. Atipamezole pretreatment significantly improved performance on the stages of the attentional task requiring an extradimensional shift in attention, and those involving stimulus reversals, whereas clonidine had no effect at any stage. In experiment 2, we then tested effects of microinjecting α₁- or β-adrenergic receptor antagonists into medial prefrontal cortex on the enhancement of performance on the extradimensional task produced by atipamezole. The atipamezole-induced enhancement of performance on the extradimensional set shifting task was blocked by α₁-, but not β-adrenergic receptor antagonists in medial prefrontal cortex. Neither antagonist alone had any effect on extradimensional set shift performance in the absence of atipamezole-induced enhancement. These results indicate that elevating noradrenergic activity at α₁-receptors in medial prefrontal cortex facilitates cognitive performance of rats in an attentional set-shifting task, which may contribute to the role of norepinephrine in behavioral state changes such as arousal, or to the beneficial cognitive effects of psychotherapeutic drugs that target noradrenergic neurotransmission.
Modulatory effects of norepinephrine, acting on alpha1 receptors in the central nucleus of the amygdala, on behavioral and neuroendocrine responses to acute immobilization stress
2002, Neuropharmacology
The central nucleus of the amygdala (CeA) is a component of the limbic fear–anxiety circuit, and has also been implicated in regulation of the hypothalamic–pituitary–adrenal (HPA) stress axis. The CeA receives dense noradrenergic innervation, and is rich in expression of α₁-adrenergic receptors. We hypothesized that norepinephrine (NE), acting on α₁ receptors in CeA, may modulate stress-induced anxiety-like behavioral responses and HPA activation. To investigate the role of α₁ adrenergic receptors in CeA on stress-induced behavioral reactivity, the α₁ antagonist benoxathian was microinjected bilaterally into CeA of male Sprague–Dawley rats, and anxiety-like behavioral responses to acute immobilization stress were measured on the Social Interaction (SI) test and on the Elevated Plus-maze (EPMZ). Benoxathian dose dependently blocked the reduction in SI time induced by immobilization stress, whereas β-receptor antagonists had no effect, consistent with an absence of β-receptors in CeA. By contrast, in separate experiments, benoxathian had no effect on stress-induced reduction in open-arm exploratory behavior on the EPMZ, nor on stress-induced plasma ACTH secretion. These results confirm that the SI test and EPMZ measure different aspects of behavioral stress reactivity that can be modulated independently, and likewise, that noradrenergic modulation of behavioral stress reactivity can occur independently of modulation of the HPA axis.
Modulatory effects of norepinephrine in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress
2002, Neuroscience
The brain noradrenergic system is activated by stress, and modulates the activity of forebrain regions involved in behavioral and neuroendocrine responses to stress, such as the lateral bed nucleus of the stria terminalis (BSTL). This region of the limbic forebrain receives dense noradrenergic innervation, and has been implicated in both anxiety and regulation of the hypothalamic–pituitary–adrenal axis. We hypothesized that stress-induced release of norepinephrine in the BSTL modulates anxiety-like behavioral responses to stress and activation of the hypothalamic–pituitary–adrenal stress axis.
Using microdialysis, we showed that release of norepinephrine was increased in the BSTL of male Sprague–Dawley rats during immobilization stress. In the next experiment, we then microinjected noradrenergic antagonists into the BSTL immediately prior to acute immobilization stress to examine noradrenergic modulation of behavioral stress reactivity. Either the α₁-receptor antagonist benoxathian, or a cocktail of β₁- and β₂-receptor antagonists (betaxolol+ICI 118,551) blocked the anxiety-like reduction in open-arm exploration on the elevated plus-maze, but not the reduction in social behavior induced in the social interaction test. In a third experiment, benoxathian reduced plasma levels of adrenocorticotropic hormone following stress, but β-receptor antagonists had no effect.
From these results we suggest that stress-induced norepinephrine release acts on both α₁- and β-receptors in the BSTL to facilitate anxiety-like behavioral responses on the plus-maze but not the social interaction test, and modulates hypothalamic–pituitary–adrenal axis activation via α₁-receptors only. Together with previous results in which adrenergic antagonists in central amygdala attenuated behavioral responses on the social interaction test but not the plus-maze, these observations suggest the two behavioral tests measure different dimensions of stress reactivity, and that norepinephrine facilitates different components of the stress response by region- and receptor-specific mechanisms.

View all citing articles on Scopus

View full text

Rapid communicationReversal of phenylpropanolamine anorexia in rats by the alpha-1 receptor antagonist benoxathian

Abstract

Eur. J. Pharmacol.

Neurosci. Biobehav. Rev.

Brain Res.

Pharmacol. Res. Commun.

Psychoneuroendocrinology

Neurosci. Biobehav. Rev.

Brain Res. Bull.

Brain Res. Bull.

Rapid communication
Reversal of phenylpropanolamine anorexia in rats by the alpha-1 receptor antagonist benoxathian